Kyverna Therapeutics, Inc. will host a live webcast and conference call on Dec. 15, 2025, to review topline results from Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Participants can register for the call on Kyverna’s Investor Relations webpage. KYV-101 is a cell therapy under investigation for B-cell-driven autoimmune diseases. Kyverna is focused on developing cell therapies for autoimmune diseases and is advancing its lead CAR T-cell therapy candidate, KYV-101, through late-stage clinical development. Kyverna is also conducting trials in lupus nephritis, multiple sclerosis, and rheumatoid arthritis.

Read more at GlobeNewswire: Kyverna Therapeutics to Report Topline Results from